Epidemic history and evolution of an emerging threat of international concern, the severe acute respiratory syndrome coronavirus 2
暂无分享,去创建一个
S. Pascarella | M. Ciccozzi | A. Borsetti | M. Giovanetti | E. Cella | S. Slavov | D. Benvenuto | A. Ianni | D. Sanna | M. Casu | F. Scarpa | A. Caruso | F. Caccuri | L. Santos | Alessandra Ciccozzi | Francesco Branda | Liliana Bazzani | Alessia Lai | Giangluglielmo Zehender | Antonello Maroutti
[1] P. Simmonds,et al. The evolution of SARS-CoV-2 , 2023, Nature Reviews Microbiology.
[2] A. Maruotti,et al. Is a new COVID‐19 wave coming from China due to an unknown variant of concern? Keep calm and look at the data , 2023, Journal of medical virology.
[3] K. Joyal-Desmarais,et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022 , 2023, The Lancet Respiratory Medicine.
[4] William T. Harvey,et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness , 2023, Nature Reviews Microbiology.
[5] Madhukiran Parvathaneni,et al. A Review on Strategies for COVID-19 Vaccine Development and Regulatory Requirements , 2023, Journal of Drug Delivery and Therapeutics.
[6] S. Kashima,et al. Global SARS-CoV-2 genomic surveillance: What we have learned (so far) , 2023, Infection, Genetics and Evolution.
[7] Xuping Xie,et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster , 2022, Nature Medicine.
[8] N. Kitchin,et al. Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine , 2022, bioRxiv.
[9] Xuping Xie,et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster , 2022, bioRxiv.
[10] E. C. Mattos,et al. Genomic epidemiology of the SARS-CoV-2 epidemic in Brazil , 2022, Nature Microbiology.
[11] Sahil Kumar,et al. Recent advances in the vaccine development for the prophylaxis of SARS Covid-19 , 2022, International Immunopharmacology.
[12] E. M. Souza,et al. Optical Biosensor for the Detection of Infectious Diseases Using the Copolymer F8T2 with Application to COVID-19 , 2022, Sensors.
[13] G. Whittaker,et al. Intrinsic furin-mediated cleavability of the spike S1/S2 site from SARS-CoV-2 variant B.1.1.529 (Omicron) , 2022, bioRxiv.
[14] S. Khoshnood,et al. A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19 , 2022, Frontiers in Microbiology.
[15] William T. Harvey,et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway , 2022, Nature Microbiology.
[16] O. Pybus,et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa , 2022, Nature Medicine.
[17] Jiming Zhang,et al. SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance , 2022, Frontiers in Immunology.
[18] Irena Vlatkovic,et al. COVID-19 mRNA vaccines: Platforms and current developments , 2022, Molecular Therapy.
[19] S. Zeger,et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.
[20] E. Kenawy,et al. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic , 2022, International Journal of Biological Macromolecules.
[21] D. Ivanković,et al. The experiences of 33 national COVID-19 dashboard teams during the first year of the pandemic in the World Health Organization European Region: A qualitative study , 2022, Digital health.
[22] Fei Shao,et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.
[23] M. Kraemer,et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa , 2021, Nature.
[24] S. Maurer-Stroh,et al. GISAID’s Role in Pandemic Response , 2021, China CDC weekly.
[25] Wenling Zhang,et al. The screening value of RT-LAMP and RT-PCR in the diagnosis of COVID-19: systematic review and meta-analysis , 2021, Journal of Virological Methods.
[26] D. Barouch,et al. COVID-19 Vaccines: Adenoviral Vectors. , 2021, Annual review of medicine.
[27] M. Kraemer,et al. Sharing, synthesis and sustainability of data analysis for epidemic preparedness in Europe , 2021, The Lancet Regional Health - Europe.
[28] Z. Ning,et al. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies , 2021, PLoS pathogens.
[29] A. Yılmaz,et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey , 2021, The Lancet.
[30] T. Stadler,et al. CoV-Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variants , 2021, Bioinform..
[31] Carla A. Cummins,et al. The COVID-19 Data Portal: accelerating SARS-CoV-2 and COVID-19 research through rapid open access data sharing , 2021, Nucleic Acids Res..
[32] J. Munita,et al. Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile , 2021, BMC Infectious Diseases.
[33] M. Giacca,et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets , 2021, Nature Microbiology.
[34] H. Harapan,et al. Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: A systematic review and meta-analysis , 2021, F1000Research.
[35] M. Suchard,et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil , 2021, Science.
[36] A. Fauci. The story behind COVID-19 vaccines , 2021, Science.
[37] M. Aoki,et al. Essential properties and pitfalls of colorimetric Reverse Transcription Loop-mediated Isothermal Amplification as a point-of-care test for SARS-CoV-2 diagnosis , 2021, Molecular medicine.
[38] Yan Liu,et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials , 2021, The Lancet Infectious Diseases.
[39] Sergei L. Kosakovsky Pond,et al. Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.
[40] M. Meyer,et al. Point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP , 2021, Nature Communications.
[41] Jie Zhou,et al. Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape , 2021, bioRxiv.
[42] J. Montclare,et al. Protein-based lateral flow assays for COVID-19 detection , 2021, Protein engineering, design & selection : PEDS.
[43] M. Biggerstaff,et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[44] N. Patel,et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice , 2021, Nature Communications.
[45] John S. Brownstein,et al. Data curation during a pandemic and lessons learned from COVID-19 , 2021, Nature Computational Science.
[46] Haiyong Peng,et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity , 2020, Nature Communications.
[47] Wenling Wang,et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial , 2020, The Lancet Infectious Diseases.
[48] Sarah K. Hilton,et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding , 2020, Cell.
[49] S. Scarpino,et al. Applications of predictive modelling early in the COVID-19 epidemic , 2020, The Lancet Digital Health.
[50] R. McIntyre,et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review , 2020, Journal of Affective Disorders.
[51] Cynthia Liu,et al. Assay Techniques and Test Development for COVID-19 Diagnosis , 2020, ACS central science.
[52] Oren Etzioni,et al. CORD-19: The Covid-19 Open Research Dataset , 2020, NLPCOVID19.
[53] M. Ciccozzi,et al. The 2019‐new coronavirus epidemic: Evidence for virus evolution , 2020, bioRxiv.
[54] Trevor Bedford,et al. Nextstrain: real-time tracking of pathogen evolution , 2017, bioRxiv.
[55] C. Dolea,et al. World Health Organization , 1949, International Organization.
[56] anonymous. Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – seventh update , 2020 .